Remedy Pharmaceuticals is seeking domestic and international investigators to study RP-1127 in various diseases states through grant funding.

Remedy Pharmaceuticals is seeking to license one or more TRPM4 channel inhibitors.

For these and other inquiries, email info@remedypharmaceuticals.com